Background. The usefulness of fluorine 18‐labelled deoxyglucose positron emission
tomography (PET) in the detection of unknown primary tumor in patients seen with malignant …

After potentially curative therapy of non–small cell lung cancer (NSCLC), masses or
symptoms suggestive of relapse are common but may be difficult to characterize. Early …

PET using 18F-FDG is a promising technique to monitor response in oncology.
Unfortunately, a multitude of analytic methods is in use. To date, it is not clear whether …

The treatment of non-small cell lung cancer has continued to evolve with the advent of
improved staging technologies, chemotherapeutic agents, and methods of radiation …

Accurate staging is important in small-cell lung cancer (SCLC). Patients with limited stage
may benefit from chemoradiation, whereas those with extensive stage conventionally …

Lung cancer is currently the leading cause of cancer-related death in both men and women
in most Western countries. Tumour stage is the strongest prognostic factor and the most …

There have been important recent advances in the management of inoperable non–small
cell lung cancer. Concurrent cisplatinum-or carboplatin-based chemotherapy and 60 to 64 …

Lung cancer is currently the leading cause of cancer-related death in both men and women
in most Western countries. Although 5-year survival rates have doubled from 1960s they are …

PET scanning with FDG utilises the fundamental differences in glucose metabolism between
normal cells and cancer cells to differentiate between benign and neoplastic processes. The …

During the 1990s, thoracic radiotherapy (RT) combined with chemotherapy was accepted as
a “new” gold standard for patients with good performance status locally …